EHA 2023

Multiple Myeloma

Can we combine teclistamab and nirogacestat for the treatment of RRMM?

Presented By

Dr Jeffrey Matous, Colorado Blood Cancer Institute, Colorado, USA

Trial

Phase 1, MajesTEC-2

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 15:21

Encouraging results for low-dose belantamab mafodotin plus nirogacestat in patients with RRMM

Presented By

Prof. Sebastian Grosicki, Medical University of Silesia, Poland

Trial

Phase 1/2, DREAMM 5

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 15:15

CARTITUDE-4: Cilta-cel meets expectations in lenalidomide-refractory MM

Presented By

Dr Hermann Einsele, University of Würzburg, Germany

Trial

Phase 3, CARTITUDE-4

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 15:08

Lymphoma

Non-Malignant Haematology

Investigational agent OMS906 performs well in PNH

Presented By

Dr Jens Panse, University of Aachen, Germany

Trial

Phase 1

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:32

Robust platelet responses with cevidoplenib in ITP

Presented By

Dr Jun-Ho Jang, Samung Medical Center, South Korea

Trial

Phase 2

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:23

Leukaemia

QuANTUM-First: Updated results on quizartinib in AML with FLT3-ITD

Presented By

Dr Richard Schlenk, University of Heidelberg, Germany

Trial

Phase 3, QuANTUM-First

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:54

Promising data for ziftomenib in relapsed/refractory NPM1-mutated AML

Presented By

Dr Amir Fathi, Massachusetts General Hospital, Massachusetts, USA

Trial

Phase 1/2, KOMET-001

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:51

MRD-positive patients with FLT3-ITD AML may benefit from post-transplant gilteritinib

Presented By

Dr Mark Levis, Johns Hopkins Hospital, Maryland, USA

Trial

MORPHO

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:45

Deep responses with asciminib in CML-CP  

Presented By

Prof. Timothy Hughes, University of Adelaide, Australia

Trial

Phase 3, ASCEMBL

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:41

QUIWI: First results suggest a clinical benefit of quizartinib in AML

Presented By

Dr Pau Montesinos, University of Valencia, Spain

Trial

Phase 2, QUIWI

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:38

Miscellaneous

COMMANDS trial: A paradigm shift in LR-MDS-associated anaemia

Presented By

Dr Matteo Della Porta, Humanitas Cancer Centre Milan, Italy

Trial

Phase 3, COMMANDS

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 17:39

REVIVE: Rusfertide meets the primary endpoint in PV

Presented By

Dr Marina Kremyanskaya, Mount Sinai, New York, USA

Trial

Phase 2, REVIVE

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 17:34

Mapping healthy HPSC variations to diagnose haematopoietic abnormalities

Presented By

Dr Nili Furer, Weizmann Institute of Science, Israel

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 17:28

High risk of death for individuals with C282Y/C282Y hereditary haemochromatosis and diabetes

Presented By

Dr Mathis Mottelson, Copenhagen University Hospital, Denmark

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 17:05